Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- Check4 days agoChange DetectedA new NIH grant/contract identifier was added to the study's identifiers, indicating NIH funding/contract support for the REACH3 trial.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page now records revision v3.6.5, replacing the previous v3.6.4. This indicates a small maintenance update rather than a substantive change to page content.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision tag on the page updated from v3.6.3 to v3.6.4, indicating a new release of the page's content-management or rendering logic.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision: v3.6.3 replaces v3.6.1 on the page, signaling a software update to the site. The study content and data remain unchanged as a result of this update.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page’s revision label has been updated from Revision: v3.6.0 to Revision: v3.6.1. This is a minor metadata update that does not alter the study content or data presented.SummaryDifference0.0%

- Check89 days agoChange DetectedThe page shows a new Revision: v3.5.5 label, replacing the previous Revision: v3.5.4. This indicates an update to the page's revision history rather than a change to study content.SummaryDifference0.0%

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.